ClinicalTrials.gg
CompletedNCT01001104Updated Sep 28, 2015Results posted

A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

A Phase 2 interventional study of LY2189265 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 6 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-28.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
30th of 54
145 · median 159
Started
2009
the only one that year
Phase 2
5 of 54
none open now
Registered
4th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 30th largest by enrollment, is the only one that started in 2009, is one of 5 in phase 2, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Metabolic Diseases
  • Glucose Metabolism Disorders
  • Diabetes
  • GLP-1
  • Lilly
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese patients with type 2 diabetes with a (BMI)≥18.5 kilograms per square meter (kg/m\^2) but \<40.0 kg/m\^2.
  • Patients who are oral antidiabetic drug (OAD) naïve or are taking OAD monotherapy except for a dipeptidyl peptidase-4 inhibitor (DPP-IV) and are willing to discontinue their OAD.
  • Patients who are OAD naïve with screening glycosylated () value of 7.0% to 9.5% and randomization HbA1c value of 7.0% to 9.5%, or who are taking OAD monotherapy with screening HbA1c value of 6.0% to 8.5% and randomization HbA1c value of 7.0% to 9.5%.
  • Patients who have, in the opinion of the investigator, a stable weight during the 12 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Patients who are currently taking prescription medications to promote weight loss
  • Patients who are receiving chronic systemic therapy, or have received such therapy within 4 weeks immediately prior to screening.
  • Patients who have a known gastrointestinal disorder, have undergone excision of all or any part of the gastrointestinal tract, have undergone gastric bypass surgery for treatment of obesity, or chronically take drugs that directly influence gastrointestinal motility.
  • Patients who have poorly controlled hypertension, renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension.
  • Patients who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis or acute pancreatitis. Patients who have amylase and/or lipase of 1.5 times or more the upper limit of the reference range.
  • Have a family history, obvious clinical signs, or symptoms of medullary carcinoma of thyroid.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    0.75 mg LY2189265

    Drug: LY2189265

  • Experimental
    0.5 mg LY2189265

    Drug: LY2189265

  • Experimental
    0.25 mg LY2189265

    Drug: LY2189265

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.

  • DrugPlacebo

    Administered by SC injection, QW for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks

    Change in HbA1c from baseline following 12 weeks of therapy (that is, HbA1c at week 12 minus HbA1c at baseline). Changes in HbA1c were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<7% up to 12 Weeks

    Percentage of participants who achieved HbA1c\<7% up to the 12-week endpoint.

    Time frame: up to 12 weeks

  2. Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<6.5% up to 12 Weeks

    Percentage of participants achieving HbA1c\<6.5% up to the 12-week endpoint.

    Time frame: up to 12 weeks

  3. Change From Baseline in Fasting Blood Glucose (FBG) Values to 12 Weeks

    Change in FBG following 12 weeks of therapy (that is, FBG at week 12 minus FBG at baseline). The change in FBG was analyzed using a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

    Time frame: Baseline, 12 weeks

  4. Change From Baseline in the Mean Daily Blood Glucose (Based on Self-Monitoring Blood Glucose [SMBG]) at 12 Weeks

    SMBG levels were measured at the following 7 timepoints during the day: fasting prebreakfast, 2 hours postbreakfast, prior to lunch, 2 hours postlunch, prior to dinner, 2 hours postdinner, and prior to bed. The change in mean daily blood glucose was analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, and dose\*visit, where the participant was treated as a random effect.

    Time frame: Baseline, 12 weeks

  5. Change From Baseline in Total Body Weight at 12 Weeks

    Changes in body weight were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

    Time frame: Baseline, 12 weeks

  6. Change From Baseline in Insulin Sensitivity Using the Updated Homeostasis Model Assessment Insulin Sensitivity (HOMA2-S) at 12 Weeks

    HOMA2-S is an estimated insulin sensitivity based on updated HOMA2 model. The HOMA2 model is a computer model that estimates insulin sensitivity (%S) as percentages of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-S were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

    Time frame: Baseline, 12 weeks

  7. Change From Baseline in Beta-Cell Function Using the Updated Homeostasis Model Assessment Beta-Cell Function (HOMA2-B) at 12 Weeks

    HOMA2-B is an estimated steady state beta cell function based on updated HOMA2 model. The HOMA2 model estimates steady state pancreatic beta cell function (%B) as a percentage of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-B were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

    Time frame: Baseline, 12 weeks

  8. Steady-State Concentrations of LY2189265

    Evaluable pharmacokinetics (PK) concentrations from all sampling time-points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at 12 weeks. The model predicted LY2189265 steady state concentrations in each dose level were calculated as estimated area under the curve (AUC)/dosing period of 168 hours. The models and model parameters were described by nonlinear, mixed-effects regression modeling (NONMEM) using the program NONMEM 7®.

    Time frame: 12 weeks

  9. Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period

    Assessed the percentage of participants who reported a hypoglycemic episode during the 12-week treatment period. Hypoglycemia was defined as a measured plasma glucose level of ≤70 milligrams per deciliter (mg/dL) or ≤3.9 millimoles per liter (mmol/L).

    Time frame: 12 weeks

07

Results

Posted Sep 28, 2015

Participant flow

Participant flow — Overall Study
Milestone0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Started35373637
Completed33363534
Not completed2113
Withdrew: Adverse event2100
Withdrew: Lost to follow-up0010
Withdrew: Entry criteria not met0001
Withdrew: Withdrawal by subject0002

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks

Change in HbA1c from baseline following 12 weeks of therapy (that is, HbA1c at week 12 minus HbA1c at baseline). Changes in HbA1c were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · percentage glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks
percentage glycosylated hemoglobin0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks-1.35 (-1.53 to -1.18)-1.15 (-1.32 to -0.98)-0.90 (-1.07 to -0.73)-0.18 (-0.36 to -0.01)
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <.001 (This is the p-value for the linear trend test at 12 weeks.)
  • 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -0.72
  • 0.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -0.97
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 · Least squares mean difference: -1.17
SecondaryPercentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<7% up to 12 Weeks

Percentage of participants who achieved HbA1c\<7% up to the 12-week endpoint.

Time frame:
up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<7% up to 12 Weeks
percentage of participants0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<7% up to 12 Weeks77.159.547.210.8
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Cochran-Armitage · p = <0.001 (This is the p-value from the Cochran-Armitage trend test.)
  • 0.25 mg LY2189265 vs Placebo · Fisher Exact · p = <0.001
  • 0.5 mg LY2189265 vs Placebo · Fisher Exact · p = <0.001
  • 0.75 mg LY2189265 vs Placebo · Fisher Exact · p = <0.001
SecondaryPercentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<6.5% up to 12 Weeks

Percentage of participants achieving HbA1c\<6.5% up to the 12-week endpoint.

Time frame:
up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<6.5% up to 12 Weeks
percentage of participants0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<6.5% up to 12 Weeks34.324.38.32.7
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Cochran-Armitage · p = <0.001 (This is the p-value from the Cochran-Armitage trend test.)
  • 0.25 mg LY2189265 vs Placebo · Fisher Exact · p = 0.358
  • 0.5 mg LY2189265 vs Placebo · Fisher Exact · p = 0.014
  • 0.75 mg LY2189265 vs Placebo · Fisher Exact · p = <0.001
SecondaryChange From Baseline in Fasting Blood Glucose (FBG) Values to 12 Weeks

Change in FBG following 12 weeks of therapy (that is, FBG at week 12 minus FBG at baseline). The change in FBG was analyzed using a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Blood Glucose (FBG) Values to 12 Weeks
milligrams per deciliter (mg/dL)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Change From Baseline in Fasting Blood Glucose (FBG) Values to 12 Weeks-37.48 (-47.00 to -27.97)-28.55 (-37.68 to -19.41)-29.21 (-38.45 to -19.97)-9.00 (-18.39 to 0.38)
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (This is the p-value for the linear trend test at week 12.)
  • 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.003 (Primary comparisons are based on the MMRM Least Squares (LS) Mean Value at week 12.) · Least squares mean difference: -20.20
  • 0.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.003 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: -19.54
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: -28.48
SecondaryChange From Baseline in the Mean Daily Blood Glucose (Based on Self-Monitoring Blood Glucose [SMBG]) at 12 Weeks

SMBG levels were measured at the following 7 timepoints during the day: fasting prebreakfast, 2 hours postbreakfast, prior to lunch, 2 hours postlunch, prior to dinner, 2 hours postdinner, and prior to bed. The change in mean daily blood glucose was analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, and dose\*visit, where the participant was treated as a random effect.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in the Mean Daily Blood Glucose (Based on Self-Monitoring Blood Glucose [SMBG]) at 12 Weeks
milligrams per deciliter (mg/dL)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Change From Baseline in the Mean Daily Blood Glucose (Based on Self-Monitoring Blood Glucose [SMBG]) at 12 Weeks-48.99 (-58.47 to -39.51)-53.12 (-61.84 to -44.41)-40.70 (-49.67 to -31.73)-7.49 (-17.44 to 2.45)
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (This is the p-value for the linear trend test at week 12.)
  • 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Primary comparisons are based on the MMRM Least Squares (LS) Mean Value at week 12.) · Least squares mean difference: -33.20
  • 0.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: -45.63
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: -41.49
SecondaryChange From Baseline in Total Body Weight at 12 Weeks

Changes in body weight were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Total Body Weight at 12 Weeks
kilograms (kg)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Change From Baseline in Total Body Weight at 12 Weeks-0.58 (-1.21 to 0.05)-0.40 (-1.01 to 0.22)0.41 (-0.20 to 1.03)-0.84 (-1.46 to -0.22)
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.987 (This is the p-value for the linear trend test at week 12.)
  • 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.005 (Primary comparisons are based on the MMRM Least Squares (LS) Mean Value at week 12.) · Least squares mean difference: 1.26
  • 0.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.311 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: 0.45
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.556 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: 0.26
SecondaryChange From Baseline in Insulin Sensitivity Using the Updated Homeostasis Model Assessment Insulin Sensitivity (HOMA2-S) at 12 Weeks

HOMA2-S is an estimated insulin sensitivity based on updated HOMA2 model. The HOMA2 model is a computer model that estimates insulin sensitivity (%S) as percentages of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-S were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · percentage insulin sensitivity (%S)
Change From Baseline in Insulin Sensitivity Using the Updated Homeostasis Model Assessment Insulin Sensitivity (HOMA2-S) at 12 Weeks
percentage insulin sensitivity (%S)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Change From Baseline in Insulin Sensitivity Using the Updated Homeostasis Model Assessment Insulin Sensitivity (HOMA2-S) at 12 Weeks-4.66 (-17.64 to 8.32)-6.07 (-18.60 to 6.46)4.65 (-7.68 to 16.97)3.74 (-8.88 to 16.36)
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.202 (This is the p-value from the linear trend test at week 12.)
  • 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.917 (Primary comparisons are based on the MMRM Least Squares (LS) Mean Value at week 12.) · Least squares mean difference: 0.91
  • 0.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.264 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: -9.81
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.346 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: -8.40
SecondaryChange From Baseline in Beta-Cell Function Using the Updated Homeostasis Model Assessment Beta-Cell Function (HOMA2-B) at 12 Weeks

HOMA2-B is an estimated steady state beta cell function based on updated HOMA2 model. The HOMA2 model estimates steady state pancreatic beta cell function (%B) as a percentage of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-B were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · percentage beta-cell function
Change From Baseline in Beta-Cell Function Using the Updated Homeostasis Model Assessment Beta-Cell Function (HOMA2-B) at 12 Weeks
percentage beta-cell function0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Change From Baseline in Beta-Cell Function Using the Updated Homeostasis Model Assessment Beta-Cell Function (HOMA2-B) at 12 Weeks38.63 (29.36 to 47.90)26.67 (17.74 to 35.61)20.04 (11.19 to 28.89)6.94 (-2.10 to 15.98)
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (This is the p-value for the linear trend test at week 12.)
  • 0.25 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.036 (Primary comparisons are based on the MMRM Least Squares (LS) Mean Value at week 12.) · Least squares mean difference: 13.10
  • 0.5 mg LY2189265 vs Placebo · Mixed Models Analysis · p = 0.002 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: 19.73
  • 0.75 mg LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Primary comparisons are based on the MMRM LS Mean Value at week 12.) · Least squares mean difference: 31.68
SecondarySteady-State Concentrations of LY2189265

Evaluable pharmacokinetics (PK) concentrations from all sampling time-points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at 12 weeks. The model predicted LY2189265 steady state concentrations in each dose level were calculated as estimated area under the curve (AUC)/dosing period of 168 hours. The models and model parameters were described by nonlinear, mixed-effects regression modeling (NONMEM) using the program NONMEM 7®.

Time frame:
12 weeks
Reported as:
Median · nanograms per milliliter (ng/mL)
Steady-State Concentrations of LY2189265
nanograms per milliliter (ng/mL)LY 0.25 mgLY 0.50 mgLY 0.75 mg
Steady-State Concentrations of LY218926515.8 (10.4 to 27.0)28.8 (19.2 to 47.4)42.7 (24.3 to 70.0)
SecondaryPercentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period

Assessed the percentage of participants who reported a hypoglycemic episode during the 12-week treatment period. Hypoglycemia was defined as a measured plasma glucose level of ≤70 milligrams per deciliter (mg/dL) or ≤3.9 millimoles per liter (mmol/L).

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period
percentage of participants0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Placebo
Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period5.72.70.00.0
Statistical analysis
  • 0.75 mg LY2189265 vs 0.5 mg LY2189265 vs 0.25 mg LY2189265 vs Placebo · Cochran-Armitage · p = 0.073 (This is the p-value from the Cochran-Armitage trend test (dose-effect).)
  • 0.5 mg LY2189265 vs Placebo · Fisher Exact · p = 1.00
  • 0.75 mg LY2189265 vs Placebo · Fisher Exact · p = 0.233

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/37 (0%)16/37 (43.2%)
0.25 mg LY2189265—1/36 (2.8%)17/36 (47.2%)
0.5 mg LY2189265—0/37 (0%)18/37 (48.6%)
0.75 mg LY2189265—1/35 (2.9%)15/35 (42.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo0.25 mg LY21892650.5 mg LY21892650.75 mg LY2189265
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/370/360/371/35
VIIth nerve paralysisNervous system disorders0/371/360/370/35
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPlacebo0.25 mg LY21892650.5 mg LY21892650.75 mg LY2189265
NauseaGastrointestinal disorders0/370/366/372/35
NasopharyngitisInfections and infestations6/373/363/373/35
ConstipationGastrointestinal disorders0/370/360/373/35
HeadacheNervous system disorders1/370/363/370/35
Seasonal allergyImmune system disorders1/372/360/372/35
Blood triglycerides increasedInvestigations0/372/360/370/35
Abdominal pain upperGastrointestinal disorders0/370/362/370/35
DiarrhoeaGastrointestinal disorders2/371/361/371/35
Abdominal discomfortGastrointestinal disorders0/371/361/371/35
Abdominal distensionGastrointestinal disorders0/370/360/371/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265PlaceboTotal
Mean52.23 ± 7.8052.50 ± 9.1752.26 ± 8.8251.70 ± 9.6752.17 ± 8.82
Sex: Female, Male
Sex: Female, Male(Participants)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265PlaceboTotal
Female7149838
Male28232729107
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265PlaceboTotal
Japanese35373637145
Region of Enrollment
Region of Enrollment(participants)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265PlaceboTotal
Japan35373637145
Percentage of Glycosylated Hemoglobin (HbA1c)
Percentage of Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265PlaceboTotal
Mean8.01 ± 0.637.98 ± 0.668.05 ± 0.667.98 ± 0.648.00 ± 0.64
Fasting Blood Glucose (FBG)
Fasting Blood Glucose (FBG)(milligrams per deciliter (mg/dL))0.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265PlaceboTotal
Mean156.51 ± 26.43150.95 ± 29.31158.75 ± 35.62159.65 ± 33.29156.45 ± 31.26
08

Study locations

6 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 276-0049, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 359-1161, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kochi, 781-8555, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyoto, 604-8151, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 530-0047, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 171-0021, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 4 years 9 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2009
First posted
Oct 23, 2009
Start
Oct 2009
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results delay requested
Apr 5, 2011
Results first posted
Sep 28, 2015
Last update
Sep 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01001104
Responsible party
Sponsor
First posted
Oct 23, 2009
Start date
Oct 2009
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Sep 28, 2015
Last update
Sep 28, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion